• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    VivoPower Terminates $180 Million F-3 Registration Statement

    3/18/26 9:00:00 AM ET
    $VIVO
    Power Generation
    Utilities
    Get the next $VIVO alert in real time by email

    Decision reflects commitment to a strategy of non dilutive funding

    Alternative potential capital sources available at project level

    LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a leading B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced that it has formally terminated its Form F-3 registration statement, originally dated December 23, 2025 (the "F-3 Registration Statement").

    Effective immediately, the F-3 Registration Statement is no longer available to the Company, and no further sales of ordinary shares will be made pursuant to that filing. This decision underscores the Board's commitment to a non-dilutive capital strategy and reflects management's confidence in the Company's current and projected cash flow from operations and alternative potential non dilutive funding sources.

    About VivoPower

    Originally founded in 2014 and listed on Nasdaq since 2016, VivoPower is an award-winning B Corporation with a global footprint spanning the United Kingdom, Australia, North America, Europe, the Middle East, and Southeast Asia. Today, VivoPower's mission is to be the independent, trusted partner for sovereign nations that develop and operate sustainable data center infrastructure, ensuring sovereign control over power, data, and national intelligence. In doing so, VivoPower helps sovereign nations bridge the gap between their energy assets and their AI ambitions by providing the Power-to-X infrastructure necessary to build and control their own domestic intelligence hubs.

    Forward-Looking Statements

    This communication includes certain statements that may constitute "forward-looking statements" for purposes of the U.S. federal securities laws. Forward-looking statements include, but are not limited to, statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for example, statements about the achievement of performance hurdles, or the benefits of the events or transactions described in this communication and the expected returns therefrom. These statements are based on VivoPower's management's current expectations or beliefs and are subject to risk, uncertainty, and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive and/or regulatory factors, and other risks and uncertainties affecting the operation of VivoPower's business. These risks, uncertainties and contingencies include changes in business conditions, fluctuations in customer demand, changes in accounting interpretations, management of rapid growth, intensity of competition from other providers of products and services, changes in general economic conditions, geopolitical events and regulatory changes, and other factors set forth in VivoPower's filings with the United States Securities and Exchange Commission. The information set forth herein should be read in light of such risks. VivoPower is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements whether as a result of new information, future events, changes in assumptions or otherwise.

    Contact 

    Shareholder Enquiries 

    [email protected] 



    Primary Logo

    Get the next $VIVO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VIVO

    DatePrice TargetRatingAnalyst
    2/7/2022$28.00 → $30.00Buy
    HC Wainwright & Co.
    11/15/2021$27.00 → $28.00Buy
    HC Wainwright & Co.
    8/9/2021$30.00 → $27.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $VIVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target

    HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $30.00 from $28.00 previously

    2/7/22 6:13:53 AM ET
    $VIVO
    Power Generation
    Utilities

    HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target

    HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $28.00 from $27.00 previously

    11/15/21 6:32:31 AM ET
    $VIVO
    Power Generation
    Utilities

    HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target

    HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $27.00 from $30.00 previously

    8/9/21 6:33:26 AM ET
    $VIVO
    Power Generation
    Utilities

    $VIVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 10, 2021 - Coronavirus (COVID-19) Update: December 10, 2021

    For Immediate Release: December 10, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On December 9, 2021, the FDA updated the SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests web page to share the latest information. The update added new information about the Meridian Bioscience, Inc. Revogene SARS-CoV-2 test, inc

    12/10/21 1:56:40 PM ET
    $VIVO
    Power Generation
    Utilities

    $VIVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Williams Felicia returned 10,274 shares to the company, closing all direct ownership in the company

    4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)

    1/31/23 2:22:23 PM ET
    $VIVO
    Power Generation
    Utilities

    SEC Form 4: Sazdanoff Catherine returned 16,424 shares to the company, closing all direct ownership in the company

    4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)

    1/31/23 2:21:33 PM ET
    $VIVO
    Power Generation
    Utilities

    SEC Form 4: Rice John Mccune Jr. returned 27,449 shares to the company, closing all direct ownership in the company

    4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)

    1/31/23 2:20:26 PM ET
    $VIVO
    Power Generation
    Utilities

    $VIVO
    SEC Filings

    View All

    SEC Form 15-12G filed by Meridian Bioscience Inc.

    15-12G - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)

    2/13/23 4:31:51 PM ET
    $VIVO
    Power Generation
    Utilities

    SEC Form 10-Q filed by Meridian Bioscience Inc.

    10-Q - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)

    2/9/23 8:23:24 AM ET
    $VIVO
    Power Generation
    Utilities

    SEC Form EFFECT filed by Meridian Bioscience Inc.

    EFFECT - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)

    2/6/23 12:15:16 AM ET
    $VIVO
    Power Generation
    Utilities

    $VIVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VivoPower Terminates $180 Million F-3 Registration Statement

    Decision reflects commitment to a strategy of non dilutive funding Alternative potential capital sources available at project level LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a leading B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced that it has formally terminated its Form F-3 registration statement, originally dated December 23, 2025 (the "F-3 Registration Statement"). Effective immediately, the F-3 Registration Statement is no longer available to the Company, and no further sales of ordinary shares will be made pursuant to that filing. Th

    3/18/26 9:00:00 AM ET
    $VIVO
    Power Generation
    Utilities

    SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience

    CINCINNATI and SEOUL, South Korea, Jan. 31, 2023 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium"), announced today that they have completed the transaction to acquire Meridian. Under the terms of the merger, Meridian shareholders have the right to receive $34.00 per share in cash. Meridian stock will no longer be traded on the NASDAQ Global Select Market. Meridian will cont

    1/31/23 1:56:00 PM ET
    $VIVO
    Power Generation
    Utilities

    DoubleVerify Holdings to Join S&P SmallCap 600

    NEW YORK, Jan. 25, 2023 /PRNewswire/ -- DoubleVerify Holdings Inc. (NYSE:DV) will replace Meridian Bioscience Inc. (NASD: VIVO) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 31. SD Biosensor is acquiring Meridian Bioscience in a deal expected to be completed soon pending final conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector January 31, 2023 S&P SmallCap 600 Addition DoubleVerify Holdings DV Inf

    1/25/23 5:58:00 PM ET
    $DV
    $SPGI
    $VIVO
    Computer Software: Programming Data Processing
    Technology
    Finance: Consumer Services
    Finance

    $VIVO
    Financials

    Live finance-specific insights

    View All

    Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction

    Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners CINCINNATI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium") announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an a

    7/7/22 7:17:00 AM ET
    $VIVO
    Power Generation
    Utilities

    MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS

    CINCINNATI, May 6, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the second quarter ended March 31, 2022. Second Quarter Fiscal 2022 Highlights (Comparison to Second Quarter Fiscal 2021): Consolidated net revenues totaled $111.2 million, the highest in Company history, with both segments ahead of expectationsLife Science segment delivered record net revenues of $70.1 millionDiagnostics segment net revenues increased 29% year-over-year to a record $41.1 millionLaunched Lyo-Ready™ sample specific master mixes for bloodResumed

    5/6/22 8:00:00 AM ET
    $VIVO
    Power Generation
    Utilities

    Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities

    CINCINNATI, Ohio, May 2, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc.  The transaction closed on April 30, 2022. EUPROTEIN Inc. offers custom development and production of high-quality bioresearch reagents, with a particular focus on human and other mammalian proteins and recombinant monoclonal antibodies.  This acquisition will help

    5/2/22 8:47:00 AM ET
    $VIVO
    Power Generation
    Utilities

    $VIVO
    Leadership Updates

    Live Leadership Updates

    View All

    Meridian Bioscience Announces Retirement of CFO Bryan Baldasare

    CINCINNATI, Dec. 2, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Bryan Baldasare, Executive Vice President, Chief Financial Officer, and Secretary, will retire from Meridian effective December 31, 2021.  The Company is engaging an executive search firm in the recruitment of a new chief financial officer.  The Company appointed Julie Smith to the position of Senior Vice President, Controller, effective December 6, 2021, and principal accounting officer, effective January 1, 2022.

    12/2/21 8:00:00 AM ET
    $VIVO
    Power Generation
    Utilities

    Meridian Bioscience Announces Retirement of Chairman David Phillips

    CINCINNATI, Nov. 24, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that David Phillips, Chairman of the Board of Directors, will retire from the Board of Directors and not seek re-election when his term ends in January 2022.  The Board of Directors will elect a new chair when Mr. Phillips' term expires and will not replace the vacated seat, which will reduce the number of directors to eight. Mr. Phillips joined the Meridian Board of Directors in 2000 and ha

    11/24/21 9:05:00 AM ET
    $VIVO
    Power Generation
    Utilities

    $VIVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Meridian Bioscience Inc. (Amendment)

    SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)

    2/9/23 11:27:43 AM ET
    $VIVO
    Power Generation
    Utilities

    SEC Form SC 13D/A filed by Meridian Bioscience Inc. (Amendment)

    SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)

    2/3/23 2:06:19 PM ET
    $VIVO
    Power Generation
    Utilities

    SEC Form SC 13G/A filed by Meridian Bioscience Inc. (Amendment)

    SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)

    1/31/23 11:06:04 AM ET
    $VIVO
    Power Generation
    Utilities